RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.The aim of this study answer the following questions:Changes in the mortality risk profile of these patients after treatment administration.Baseline characteristics of patients initiating Selexipag.Parameters used for risk stratification prior to treatment escalation.Events during follow-up.No comparison group available

Inclusion Criteria:They agree to participate in the study by signing an informed consent formExclusion Criteria:Decline to participate in the studyPatients living 6 months or less in the reference health areaPatients with active malignant tumors